Glucocorticoids are steroid hormones used as anti-inflammatory treatments. However, this strong immunomodulation causes undesirable side effects that impair bones, such as osteoporosis. Glucocorticoid therapy is a major risk factor for developing steroid-induced osteonecrosis of the femur head (ONFH). Since ONFH is incurable, therapy with mesenchymal stem cells (MSCs) that can differentiate into osteoblasts are a first-line choice. Bone marrow-derived MSCs (BM-MSCs) are often used as a source of stem cell therapy for ONFH, but their proliferative activity is impaired after steroid treatment. Adipose tissue-derived MSCs (AT-MSCs) may be an attractive alternative source; however, it is unknown whether AT-MSCs from steroid-induced ONFH (sAT-MSCs) have the same differentiation ability as BM-MSCs or normal AT-MSCs (nAT-MSCs). In this study, we demonstrate that nAT-MSCs chronically exposed to glucocorticoids show lower alkaline phosphatase activity leading to reduced osteogenic differentiation ability. This impaired osteogenesis is mediated by high expression of Dickkopf1 (Dkk-1) that inhibits wnt/β-catenin signaling. Increased Dkk-1 also causes impaired osteogenesis along with reductions in bone regenerative capacity in sAT-MSCs. Of note, plasma Dkk-1 levels are elevated in steroid-induced ONFH patients. Collectively, our findings suggest that glucocorticoid-induced expression of Dkk-1 could be a key factor in modulating the differentiation ability of MSCs used for ONFH and other stem cell therapies.
Get full access to this article
View all access options for this article.
References
1.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopD and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
2.
UccelliA, MorettaL and PistoiaV. (2008). Mesenchymal stem cells in health and disease. Nat Rev Immunol, 8:726–736.
3.
TrinhNT, YamashitaT, OhnedaK, KimuraK, SalazarGT, SatoF and OhnedaO. (2016). Increased expression of EGR-1 in diabetic human adipose tissue-derived mesenchymal stem cells reduces their wound healing capacity. Stem Cells Dev, 25:760–773.
4.
KhanhVC, OhnedaK, KatoT, YamashitaT, SatoF, TachiK and OhnedaO. (2017). Uremic toxins affect the imbalance of redox state and overexpression of prolyl hydroxylase 2 in human adipose tissue-derived mesenchymal stem cells involved in wound healing. Stem Cells Dev, 26:948–963.
5.
YamanakaS, YokoteS, YamadaA, KatsuokaY, IzuharaL, ShimadaY, OmuraN, OkanoHJ, OhkiT and YokooT. (2014). Adipose tissue-derived mesenchymal stem cells in long-term dialysis patients display downregulation of PCAF expression and poor angiogenesis activation. PLoS One, 9:e102311.
6.
SerenaC, KeiranN, Ceperuelo-MallafreV, EjarqueM, FraderaR, RocheK, Nunez-RoaC, VendrellJ and Fernandez-VeledoS. (2016). Obesity and type 2 diabetes alters the immune properties of human adipose derived stem cells. Stem Cells, 34:2559–2573.
7.
KatoT, KhanhVC, SatoK, TakeuchiK, CarolinaE, YamashitaT, SugayaH, YoshiokaT, MishimaH and OhnedaO. (2017). SDF-1 improves wound healing ability of glucocorticoid-treated adipose tissue-derived mesenchymal stem cells. Biochem Biophys Res Commun, 493:1010–1017.
8.
SchleimerR. (1993). An overview of glucocorticoid anti-inflammatory actions. Eur J Pharmacol, 45:S3–S7.
9.
SchäckeH, DöckeW-D and AsadullahK. (2002). Mechanisms involved in the side effects of glucocorticoids. Pharmacol Therapeut, 96:23–43.
CooperMS and HardyR. (2011). Glucocorticoid-induced osteoporosis—a disorder of mesenchymal stromal cells?. Front Endocrinol (Lausanne), 2:24.
12.
LukertBP and RaiszLG. (1990). Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med, 112:352–364.
13.
CleversH. (2006). Wnt/β-catenin signaling in development and disease. Cell, 127:469–480.
14.
OhnakaK, TaniguchiH, KawateH, NawataH and TakayanagiR. (2004). Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun, 318:259–264.
15.
HayashiK, YamaguchiT, YanoS, KanazawaI, YamauchiM, YamamotoM and SugimotoT. (2009). BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun, 379:261–266.
16.
FisherDE and BickelWH. (1971). Corticosteroid-induced avascular necrosis. J Bone Joint Surg Am, 53:859–873.
JonesLC and HungerfordDS. (2004). Osteonecrosis: etiology, diagnosis, and treatment. Curr Opin Rheumatol, 16:443–449.
19.
UrbaniakJR, CooganPG, GunnesonEB and NunleyJA. (1995). Treatment of osteonecrosis of the femoral head with free vascularized fibular grafting. A long-term follow-up study of one hundred and three hips. J Bone Joint Surg, 77:681–694.
20.
TranTC, KimuraK, NaganoM, YamashitaT, OhnedaK, SugimoriH, SatoF, SakakibaraY, HamadaH and YoshikawaH. (2011). Identification of human placenta-derived mesenchymal stem cells involved in re-endothelialization. J Cell Physiol, 226:224–235.
21.
MostafaNZ, FitzsimmonsR, MajorPW, AdesidaA, JomhaN, JiangH and UludağH. (2012). Osteogenic differentiation of human mesenchymal stem cells cultured with dexamethasone, vitamin D3, basic fibroblast growth factor, and bone morphogenetic protein-2. Connect Tissue Res, 53:117–131.
22.
ChengS-L, YangJW, RifasL, ZhangS-F and AvioliLV. (1994). Differentiation of human bone marrow osteogenic stromal cells in vitro: induction of the osteoblast phenotype by dexamethasone. Endocrinology, 134:277–286.
23.
YaoW, ChengZ, PhamA, BusseC, ZimmermannEA, RitchieRO and LaneNE. (2008). Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum, 58:3485–3497.
24.
SatoK, ItohT, KatoT, KitamuraY, KaulSC, WadhwaR, SatoF and OhnedaO. (2015). Serum-free isolation and culture system to enhance the proliferation and bone regeneration of adipose tissue-derived mesenchymal stem cells. In Vitro Cell Dev Biol Anim, 51:515–529.
25.
KimuraK, NaganoM, SalazarG, YamashitaT, TsuboiI, MishimaH, MatsushitaS, SatoF, YamagataK and OhnedaO. (2013). The role of CCL5 in the ability of adipose tissue-derived mesenchymal stem cells to support repair of ischemic regions. Stem Cells Dev, 23:488–501.
26.
NaganoM, KimuraK, YamashitaT, OhnedaK, NozawaD, HamadaH, YoshikawaH, OchiaiN and OhnedaO. (2010). Hypoxia responsive mesenchymal stem cells derived from human umbilical cord blood are effective for bone repair. Stem Cells Dev, 19:1195–1210.
27.
YoshiokaT, MishimaH, AkaogiH, SakaiS, LiM and OchiaiN. (2011). Concentrated autologous bone marrow aspirate transplantation treatment for corticosteroid-induced osteonecrosis of the femoral head in systemic lupus erythematosus. Int Orthop, 35:823–829.
28.
KajiyamaS, UjiieY, NishikawaS, InoueK, ShirakawaS, HanadaN, LiddellR, DaviesJE and GomiK. (2015). Bone formation by human umbilical cord perivascular cells. J Biomed Mater Res A, 103:2807–2814.
29.
HernigouP, BeaujeanF and LambotteJ. (1999). Decrease in the mesenchymal stem-cell pool in the proximal femur in corticosteroid-induced osteonecrosis. Bone Joint J, 81:349–355.
30.
WangBL, SunW, ShiZC, LouJN, ZhangNF, ShiSH, GuoWS, ChengLM, YeLY and ZhangWJ. (2008). Decreased proliferation of mesenchymal stem cells in corticosteroid-induced osteonecrosis of femoral head. Orthopedics, 31:444.
31.
WylesCC, HoudekMT, Crespo-DiazRJ, NorambuenaGA, StalboergerPG, TerzicA, BehfarA and SierraRJ. (2015). Adipose-derived mesenchymal stem cells are phenotypically superior for regeneration in the setting of osteonecrosis of the femoral head. Clin Orthop Relat Res, 473:3080–3090.
32.
SandersonM, Sadie-Van GijsenH, HoughS and FerrisWF. (2015). The role of MKP-1 in the anti-proliferative effects of glucocorticoids in primary rat pre-osteoblasts. PLoS One, 10:e0135358.
33.
HessleL, JohnsonKA, AndersonHC, NarisawaS, SaliA, GodingJW, TerkeltaubR and MillánJL. (2002). Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A, 99:9445–9449.
34.
RawadiG, VayssièreB, DunnF, BaronR and Roman-RomanS. (2003). BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res, 18:1842–1853.
35.
EtheridgeSL, SpencerGJ, HeathDJ and GeneverPG. (2004). Expression profiling and functional analysis of wnt signaling mechanisms in mesenchymal stem cells. Stem cells, 22:849–860.
36.
de BoerJ, SiddappaR, GasparC, van ApeldoornA, FoddeR and van BlitterswijkC. (2004). Wnt signaling inhibits osteogenic differentiation of human mesenchymal stem cells. Bone, 34:818–826.
37.
GaurT, LengnerCJ, HovhannisyanH, BhatRA, BodinePV, KommBS, JavedA, Van WijnenAJ, SteinJL and SteinGS. (2005). Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem, 280:33132–33140.
XieQ, WangZ, ZhouH, YuZ, HuangY, SunH, BiX, WangY, ShiW, GuP and FanX. (2016). The role of miR-135-modified adipose-derived mesenchymal stem cells in bone regeneration. Biomaterials, 75:279–294.
40.
KoE, AlbertiK, LeeJS, YangK, JinY, ShinJ, YangHS, XuQ and ChoSW. (2016). Nanostructured tendon-derived scaffolds for enhanced bone regeneration by human adipose-derived stem cells. ACS Appl Mater Interfaces, 8:22819–22829.
41.
FukushimaW, FujiokaM, KuboT, TamakoshiA, NagaiM and HirotaY. (2010). Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res, 468:2715–2724.
42.
HernigouP and BeaujeanF. (2002). Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res, 405:14–23.
43.
GangjiV, De MaertelaerV and HauzeurJ-P. (2011). Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: five year follow-up of a prospective controlled study. Bone, 49:1005–1009.
44.
SenRK, TripathySK, AggarwalS, MarwahaN, SharmaRR and KhandelwalN. (2012). Early results of core decompression and autologous bone marrow mononuclear cells instillation in femoral head osteonecrosis: a randomized control study. J Arthroplasty, 27:679–686.
45.
HoudekMT, WylesCC, PackardBD, TerzicA, BehfarA and SierraRJ. (2016). Decreased osteogenic activity of mesenchymal stem cells in patients with corticosteroid-induced osteonecrosis of the femoral head. J Arthroplasty, 31:893–898.
46.
LeeJS, LeeJS, RohHL, KimCH, JungJS and SuhKT. (2006). Alterations in the differentiation ability of mesenchymal stem cells in patients with nontraumatic osteonecrosis of the femoral head: comparative analysis according to the risk factor. J Orthop Res, 24:604–609.
SuzukiA, PalmerG, BonjourJ-P and CaverzasioJ. (1999). Regulation of alkaline phosphatase activity by p38 MAP kinase in response to activation of gi protein-coupled receptors by epinephrine in osteoblast-like cells. Endocrinology, 140:3177–3182.
49.
ShaoXR, LinSY, PengQ, ShiSR, LiXL, ZhangT and LinYF. (2017). Effect of tetrahedral DNA nanostructures on osteogenic differentiation of mesenchymal stem cells via activation of the Wnt/beta-catenin signaling pathway. Nanomedicine, 13:1809–1819.
50.
ShaoX, LinS, PengQ, ShiS, WeiX, ZhangT and LinY. (2017). Tetrahedral DNA nanostructure: a potential promoter for cartilage tissue regeneration via regulating chondrocyte phenotype and proliferation. Small 13 [Epub ahead of print];, DOI: 10.1002/smll.201602770.
51.
OrimoH. (2010). The mechanism of mineralization and the role of alkaline phosphatase in health and disease. J Nippon Med Sch, 77:4–12.
52.
FeddeKN, BlairL, SilversteinJ, CoburnSP, RyanLM, WeinsteinRS, WaymireK, NarisawaS, MillanJL, MacGregorGR and WhyteMP. (1999). Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res, 14:2015–2026.
53.
WennbergC, HessleL, LundbergP, MauroS, NarisawaS, LernerUH and MillanJL. (2000). Functional characterization of osteoblasts and osteoclasts from alkaline phosphatase knockout mice. J Bone Miner Res, 15:1879–1888.
54.
MukhopadhyayM, SinhaR, PalM, BhattacharyyaS, DanA and RoyMM. (2011). Role of common biochemical markers for the assessment of fracture union. Indian J Clin Biochem, 26:274–278.
55.
CoxG, EinhornTA, TzioupisC and GiannoudisPV. (2010). Bone-turnover markers in fracture healing. J Bone Joint Surg Br, 92:329–334.
56.
StuckiU, SchmidJ, HammerleCF and LangNP. (2001). Temporal and local appearance of alkaline phosphatase activity in early stages of guided bone regeneration. A descriptive histochemical study in humans. Clin Oral Implants Res, 12:121–127.
57.
MuljacicA, Poljak-GuberinaR, ZivkovicO, BilicV, GuberinaM and CrvenkovicD. (2013). Course and rate of post-fracture bone healing in correlation with bone-specific alkaline phosphatase and bone callus formation. Coll Antropol, 37:1275–1283.
58.
SalazarVS, GamerLW and RosenV. (2016). BMP signalling in skeletal development, disease and repair. Nat Rev Endocrinol, 12:203–221.
59.
MatsubaraT, KidaK, YamaguchiA, HataK, IchidaF, MeguroH, AburataniH, NishimuraR and YonedaT. (2008). BMP2 regulates osterix through Msx2 and Runx2 during osteoblast differentiation. J Biol Chem, 283:29119–29125.
60.
LangenbachF and HandschelJ. (2013). Effects of dexamethasone, ascorbic acid and beta-glycerophosphate on the osteogenic differentiation of stem cells in vitro. Stem Cell Res Ther, 4:117.
61.
WuLA, WangF, DonlyKJ, BakerA, WanC, LuoD, MacDougallM and ChenS. (2016). Establishment of immortalized BMP2/4 double knock-out osteoblastic cells is essential for study of osteoblast growth, differentiation, and osteogenesis. J Cell Physiol, 231:1189–1198.
62.
LiH, DaiK, TangT, ZhangX, YanM and LouJ. (2007). Bone regeneration by implantation of adipose-derived stromal cells expressing BMP-2. Biochem Biophys Res Commun, 356:836–842.
63.
TsujiK, BandyopadhyayA, HarfeBD, CoxK, KakarS, GerstenfeldL, EinhornT, TabinCJ and RosenV. (2006). BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet, 38:1424–1429.
64.
LiJ, SarosiI, CattleyRC, PretoriusJ, AsuncionF, GrisantiM, MoronyS, AdamuS, GengZ and QiuW. (2006). Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone, 39:754–766.
65.
HonsawekS, TanavaleeA, YuktanandanaP, NgarmukosS, SaetanN and TantavisutS. (2010). Dickkopf-1 (Dkk-1) in plasma and synovial fluid is inversely correlated with radiographic severity of knee osteoarthritis patients. BMC Musculoskelet Disord, 11:257.
66.
DiarraD, StolinaM, PolzerK, ZwerinaJ, OminskyMS, DwyerD, KorbA, SmolenJ, HoffmannM and ScheineckerC. (2007). Dickkopf-1 is a master regulator of joint remodeling. Nat Med, 13:156–163.
67.
ButlerJS, MurrayDW, HursonCJ, O'BrienJ, DoranPP and O'ByrneJM. (2011). The role of Dkk1 in bone mass regulation: correlating serum Dkk1 expression with bone mineral density. J Orthop Res, 29:414–418.
68.
TianE, ZhanF, WalkerR, RasmussenE, MaY, Barlogie andB, ShaughnessyJDJr. (2003). The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med, 349:2483–2494.
69.
YaoW, ChengZ, BusseC, PhamA, NakamuraMC and LaneNE. (2008). Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum, 58:1674–1686.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
